Featured Research

from universities, journals, and other organizations

International study shows efficacy of new gastric cancer drug

Date:
October 2, 2013
Source:
Vall d´Hebron Institute of Oncology (VHIO)
Summary:
The phase III study of a new drug to treat gastric cancer shows that an antibody ramucirumab inhibits the action of various proteins involved in tumour growth, prolonging survival of patients with advanced gastric cancer.  

The phase III study, published in the scientific journal, The Lancet, in which researchers at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO) have participated, shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumour growth, prolonging survival of patients with advanced gastric cancer.

Related Articles


Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death. In Western countries, most patients with gastric cancer have advanced disease at diagnosis, and treatment options are limited. This study opens a new avenue in second-line treatment of this type of cancer.

This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10 months.

The trial investigated the use of ramucirumab, an antibody developed to treat solid tumours that targets Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), a key receptor in the angiogenesis process. It showed that ramucirumab effectively inhibits a group of proteins that stimulate angiogenesis, a physiological process whereby new blood vessels are formed from pre-existing vessels, which plays a key part in malignant tumour growth. These proteins induce capillary growth in the tumour, supplying the nutrients that it needs.

The clinical trial was conducted on 355 patients with advanced gastric cancer, 238 of whom received treatment with ramucirumab, while 117 received placebo. All patients also received best supportive care. The ramucirumab treatment group showed improved median survival (5.2 months versus 3.8 months in the other group), better tumour control and a noteworthy reduction in the risk of disease progression or death. After six months of treatment with ramucirumab, patient survival in this group was 40%, while response to standard treatment was notably lower (below 20%).

Dr Josep Tabernero, Head of the Medical Oncology Department at the Vall d´Hebron University Hospital, Director of the Vall d´Hebron Institute of Oncology (VHIO), and one of the co-authors of this study, confirmed that "the results of this study are important for several reasons. First, the study revives the idea that inhibition of the angiogenesis process plays an important role in gastric cancer, which can be used to achieve results in these patients. This is important because previous studies with the drug bevacizumab -- which inhibits the vascular endothelial growth factor (VEGF) -- did not show any significant benefit in this disease. Second, the study results open new avenues for patients with gastric cancer, offering more treatment options. Thirdly, new studies combining ramucirumab with chemotherapy drugs in gastric cancer are making us very optimistic about the outcome of these combinations, because of the synergies between the drugs. This is likely to change the way we treat gastric cancer in the future."

A very aggressive cancer

Gastric cancer is the fourth most common cancer worldwide, and the second leading cause of cancer-related death. In Western countries, most patients with gastric adenocarcinoma have advanced disease at diagnosis, and treatment options are limited.

Following first-line gastric cancer chemotherapy, with a median survival of 8 to 10 months, most national medicines agencies have approved second-line treatment in patients with gastric cancer. However, we still need specific new systemic agents, based on our underlying understanding of gastric cancer biology, to improve outcomes in patients with advanced disease. This study opens a new avenue in second-line treatment of this type of cancer.


Story Source:

The above story is based on materials provided by Vall d´Hebron Institute of Oncology (VHIO). Note: Materials may be edited for content and length.


Journal Reference:

  1. Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David R Ferry, Bohuslav Melichar, Mustapha Tehfe, Eldar Topuzov, John Raymond Zalcberg, Ian Chau, William Campbell, Choondal Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M Liepa, Ling Gao, Jonathan D Schwartz, Josep Tabernero. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 2013; DOI: 10.1016/S0140-6736(13)61719-5

Cite This Page:

Vall d´Hebron Institute of Oncology (VHIO). "International study shows efficacy of new gastric cancer drug." ScienceDaily. ScienceDaily, 2 October 2013. <www.sciencedaily.com/releases/2013/10/131002212208.htm>.
Vall d´Hebron Institute of Oncology (VHIO). (2013, October 2). International study shows efficacy of new gastric cancer drug. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/10/131002212208.htm
Vall d´Hebron Institute of Oncology (VHIO). "International study shows efficacy of new gastric cancer drug." ScienceDaily. www.sciencedaily.com/releases/2013/10/131002212208.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins